Unnati Pharmax

Ibrunat Capsule
Composition: Ibrutinib Capsules 140mg
International Trade Name: Imbruvica®

Ibrunat 140 is a high-quality Ibrutinib 140mg Capsule, a bioequivalent formulation of the internationally recognized Bruton’s tyrosine kinase (BTK) inhibitor marketed under the brand name Imbruvica®. Manufactured in WHO-GMP certified facilities, Ibrunat Capsules are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in hematologic malignancies.

Ibrutinib works by selectively inhibiting BTK, a key enzyme in B-cell receptor signaling, thereby blocking the proliferation and survival of malignant B-cells. Ibrunat 140mg Capsule is primarily indicated for the treatment of chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenström’s macroglobulinemia (WM), and other B-cell malignancies, including patients with relapsed or refractory disease.

Ibrutinib 140mg capsule, Ibrunat capsule, Imbruvica biosimilar, BTK inhibitor price, hematologic cancer treatment, targeted oral oncology therapy, anticancer capsule exporter India, and oncology pharmaceutical manufacturer India.

Ibrunat Ibrutinib Capsule is manufactured under stringent GMP and oncology quality standards, ensuring consistent efficacy, safety, and long-term stability. The capsules are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology clinics, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

BOSENTAS 125 Tablet
Composition: Bosentas Tablets IP 125mg
International Trade Name: Clowil®, Odis®, Kamestin®

BOSENTAS 125 is a high-quality Bosentas 125mg Tablet, a bioequivalent formulation of the internationally recognized endothelin receptor antagonist marketed under the brand names Clowil®, Odis®, and Kamestin®. Manufactured in WHO-GMP certified facilities, BOSENTAS Tablets are supplied by trusted pharmaceutical exporters from India to support global treatment programs for pulmonary arterial hypertension (PAH) and related cardiovascular conditions.

Bosentas works by selectively blocking endothelin receptors, leading to vasodilation and reduced vascular resistance, which helps improve exercise capacity and delay disease progression in patients with pulmonary arterial hypertension. BOSENTAS 125mg Tablet is primarily indicated for the treatment of pulmonary arterial hypertension (PAH) in adults, either as monotherapy or in combination with other PAH therapies.

Bosentas 125mg tablet, BOSENTAS tablet, Clowil generic, Odis generic, Kamestin generic, endothelin receptor antagonist price, pulmonary arterial hypertension treatment, cardiovascular therapy tablets exporter India, and pharmaceutical manufacturer India.

BOSENTAS 125 Bosentas Tablet is manufactured under stringent GMP and pharmaceutical quality standards, ensuring consistent efficacy, safety, and long-term stability. The tablets are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for hospitals, specialty cardiology clinics, government health programs, and international pharmaceutical distributors.

BOSENTAS 62.5 Tablet
Composition: Bosentan Tablets IP 62.5mg
International Trade Name: Tracleer®

BOSENTAS 62.5 is a high-quality Bosentan 62.5mg Tablet, a bioequivalent formulation of the internationally recognized endothelin receptor antagonist marketed under the brand name Tracleer®. Manufactured in WHO-GMP certified facilities, BOSENTAS Tablets are supplied by trusted pharmaceutical exporters from India to support global treatment programs for pulmonary arterial hypertension (PAH) and related cardiovascular conditions.

Bosentan works by selectively blocking endothelin receptors, leading to vasodilation and reduced vascular resistance, which helps improve exercise capacity and slow disease progression in patients with pulmonary arterial hypertension. BOSENTAS 62.5mg Tablet is primarily indicated for the treatment of pulmonary arterial hypertension (PAH) in adults, including patients with WHO functional class II–III symptoms, either as monotherapy or in combination with other PAH therapies.

Bosentan 62.5mg tablet, BOSENTAS tablet, Tracleer generic, endothelin receptor antagonist price, pulmonary arterial hypertension treatment, cardiovascular therapy tablets exporter India, and pharmaceutical manufacturer India.

BOSENTAS 62.5 Bosentan Tablet is manufactured under stringent GMP and pharmaceutical quality standards, ensuring consistent efficacy, safety, and long-term stability. The tablets are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for hospitals, cardiology clinics, government health programs, and international pharmaceutical distributors.

Ramiven 150mg Tablet
Composition: Abemaciclib Tablets 150mg
International Trade Name: Verzenio® / Verzenios®

Ramiven 150 is a high-quality Abemaciclib 150mg Tablet, a bioequivalent formulation of the internationally recognized CDK4/6 inhibitor marketed under the brand name Verzenio®. Manufactured in WHO-GMP certified facilities, Ramiven Tablets are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in hormone receptor (HR)–positive, HER2-negative breast cancer.

Abemaciclib selectively inhibits cyclin-dependent kinases 4 and 6 (CDK4/6), leading to cell cycle arrest and suppression of tumor cell proliferation. Ramiven 150mg Tablet is primarily indicated for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer, used either as monotherapy or in combination with endocrine therapies such as aromatase inhibitors or fulvestrant, as per approved treatment protocols.

Ramiven 150mg Tablet is manufactured under stringent GMP and pharmaceutical quality standards to ensure consistent efficacy, safety, and batch-to-batch reliability. The product is supplied in secure, export-grade packaging with complete regulatory documentation, making it suitable for oncology hospitals, breast cancer centers, specialty pharmacies, government cancer programs, and international pharmaceutical distributors.

Anaridex 1mg Tablet
Composition: Anastrozole Tablets 1mg
International Trade Name: Arimidex®

Anaridex 1 is a high-quality Anastrozole 1mg Tablet, a bioequivalent formulation of the internationally recognized aromatase inhibitor marketed under the brand name Arimidex®. Manufactured in WHO-GMP certified facilities, Anaridex Tablets are supplied by trusted pharmaceutical exporters from India to support global oncology and hormone-therapy treatment programs, particularly in hormone receptor–positive breast cancer.

Anastrozole works by selectively inhibiting the aromatase enzyme, resulting in a significant reduction in estrogen production in postmenopausal women and thereby limiting estrogen-driven tumor growth. Anaridex 1mg Tablet is primarily indicated for the treatment of postmenopausal women with estrogen receptor (ER)–positive early or advanced breast cancer, including adjuvant therapy and management of metastatic disease.

Anaridex 1mg Tablet is manufactured under stringent GMP and pharmaceutical quality standards to ensure consistent potency, safety, and therapeutic reliability. The product is supplied in secure, export-grade packaging with complete regulatory documentation, making it suitable for oncology hospitals, breast cancer clinics, specialty pharmacies, government cancer programs, and international pharmaceutical distributors.

Xtane Tablet
Composition: Exemestane Tablets IP 25mg
International Trade Name: Aromasin®

Xtane is a high-quality Exemestane 25mg Tablet, a bioequivalent formulation of the internationally recognized steroidal aromatase inhibitor marketed under the brand name Aromasin®. Manufactured in WHO-GMP certified facilities, Xtane Tablets are supplied by trusted pharmaceutical exporters from India to support advanced global oncology and hormone therapy treatment programs.

Exemestane works by irreversibly inhibiting the aromatase enzyme, thereby reducing estrogen production in postmenopausal women. Xtane Tablet is primarily indicated for the treatment of estrogen receptor (ER)-positive breast cancer in postmenopausal women, especially in patients who have progressed following prior therapy with tamoxifen.

Exemestane 25mg tablet, Xtane tablet, Aromasin generic, aromatase inhibitor price, hormone therapy for breast cancer, postmenopausal breast cancer treatment, oncology medicine exporter India, and anticancer tablet manufacturer India.

Xtane Exemestane Tablet is manufactured under stringent GMP and pharmaceutical quality standards, ensuring consistent efficacy, safety, and long-term stability. The tablets are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology clinics, hospitals, breast cancer treatment centers, government cancer programs, and international pharmaceutical distributors.

Femistra 1mg Tablet
Composition: Anastrozole Tablets 1mg
International Trade Name: Arimidex®

Femistra 1 is a high-quality Anastrozole 1mg Tablet, a bioequivalent formulation of the internationally recognized aromatase inhibitor marketed under the brand name Arimidex®. Manufactured in WHO-GMP certified facilities, Femistra Tablets are supplied by trusted pharmaceutical exporters from India to support global oncology and hormone-therapy treatment programs, particularly in hormone receptor–positive breast cancer.

Anastrozole works by selectively inhibiting the aromatase enzyme, leading to a reduction in estrogen production in postmenopausal women and thereby suppressing estrogen-dependent tumor growth. Femistra 1mg Tablet is primarily indicated for the treatment of postmenopausal women with estrogen receptor (ER)–positive early or advanced breast cancer, including adjuvant therapy and management of metastatic disease.

Femistra 1mg Tablet is manufactured under stringent GMP and pharmaceutical quality standards to ensure consistent potency, safety, and therapeutic reliability. The product is supplied in secure, export-grade packaging with complete regulatory documentation, making it suitable for oncology hospitals, breast cancer clinics, specialty pharmacies, government cancer programs, and international pharmaceutical distributors.

Fulzos 250 Injection
Composition: Fulvestrant Injection 250mg/5ml
International Trade Name: Faslodex®

Fulzos 250 is a high-quality Fulvestrant 250mg/5ml Injection, a bioequivalent formulation of the internationally recognized selective estrogen receptor degrader (SERD) marketed under the brand name Faslodex®. Manufactured in WHO-GMP certified facilities, Fulzos Injection is supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in hormone receptor–positive breast cancer.

Fulvestrant works by binding to estrogen receptors and accelerating their degradation, thereby inhibiting estrogen-dependent tumor growth. Fulzos 250mg/5ml Injection is primarily indicated for the treatment of postmenopausal women with hormone receptor–positive, HER2-negative advanced or metastatic breast cancer, especially in patients who have progressed following prior endocrine therapy.

Fulvestrant 250mg/5ml injection, Fulzos 250 injection, Faslodex biosimilar, SERD hormone therapy, HR-positive breast cancer treatment, oncology injectable therapy, anticancer injection exporter India, and oncology pharmaceutical manufacturer India.

Fulzos 250 Fulvestrant Injection is manufactured under stringent GMP and oncology injectable quality standards, ensuring consistent efficacy, safety, and long-term stability. The injection is supplied in secure, sterile, export-grade packaging with complete regulatory documentation, making it suitable for oncology infusion centers, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Fulvekast 250 mg (Fulvestrant Injection) is a hormonal anti-cancer medication used in the treatment of hormone receptor-positive (HR+) advanced or metastatic breast cancer in women, particularly after menopause. It contains Fulvestrant 250 mg, an estrogen receptor antagonist that works by blocking and degrading estrogen receptors, thereby slowing or stopping the growth of cancer cells that depend on estrogen.

Fulvestrant is globally recognized under the well-known international brand name Faslodex® (by AstraZeneca) and is widely prescribed across the USA, Europe, and other international markets. Fulvekast 250 mg is a high-quality generic alternative that provides the same therapeutic effectiveness at a more affordable cost.

This medication is commonly used alone or in combination with other targeted therapies such as CDK 4/6 inhibitors. It plays a key role in delaying disease progression, reducing tumor growth, and improving overall survival outcomes in patients with advanced breast cancer.

Key Benefits:

• Blocks and degrades estrogen receptors

• Effective in HR+ advanced breast cancer

• Helps slow tumor growth and progression

• Improves progression-free survival

Usage Instructions:
Fulvekast 250 mg Injection is administered by a healthcare professional as an intramuscular injection, usually into the buttock. The dosage schedule is determined by the treating physician.

Safety Information:
Use under strict medical supervision. Regular monitoring of liver function and overall health is recommended during treatment. Inform your doctor about any unusual symptoms or side effects.

International Brand Names of Fulvestrant:
Faslodex®, Fulvetrant Teva, Fulvera, and other branded generics available worldwide.

Anaridex 1mg Tablet
Composition: Anastrozole Tablets 1mg
International Trade Name: Arimidex®

Anaridex 1 is a high-quality Anastrozole 1mg Tablet, a bioequivalent formulation of the internationally recognized aromatase inhibitor marketed under the brand name Arimidex®. Manufactured in WHO-GMP certified facilities, Anaridex Tablets are supplied by trusted pharmaceutical exporters from India to support global oncology and hormone-therapy treatment programs, particularly in hormone receptor–positive breast cancer.

Anastrozole works by selectively inhibiting the aromatase enzyme, resulting in a reduction of estrogen production in postmenopausal women, thereby suppressing estrogen-dependent tumor growth. Anaridex 1mg Tablet is primarily indicated for the treatment of postmenopausal women with estrogen receptor (ER)–positive early or advanced breast cancer, including adjuvant therapy and management of metastatic disease.

Anaridex 1mg Tablet is manufactured under stringent GMP and pharmaceutical quality standards to ensure consistent potency, safety, and therapeutic reliability. The product is supplied in secure, export-grade packaging with complete regulatory documentation, making it suitable for oncology hospitals, breast cancer clinics, specialty pharmacies, government cancer programs, and international pharmaceutical distributors.

Fulzos 250mg Injection is an anti-cancer medication used in the treatment of hormone receptor-positive breast cancer in postmenopausal women. It contains Fulvestrant, an estrogen receptor antagonist that works by blocking the action of estrogen, thereby slowing down or stopping the growth of cancer cells.

This medicine is administered as an intramuscular injection under the supervision of a healthcare professional. It is commonly prescribed when breast cancer is hormone-dependent and may be used alone or in combination with other therapies.

Key Features:

• Contains Fulvestrant 250mg
• Effective in hormone-dependent breast cancer
• Estrogen receptor blocker (anti-estrogen therapy)
• Long-acting intramuscular injection

Indications:

• Hormone receptor-positive breast cancer (postmenopausal women)

Common Side Effects:

• Nausea and vomiting
• Injection site pain
• Fatigue
• Back pain
• Hot flashes
• Headache

Storage:
Store in refrigerator (2°C – 8°C). Do not freeze.

Usage Instructions:
To be administered by a qualified medical professional only. Do not self-administer.

Note:
Use strictly under medical prescription.

LETZORA Tablet
Composition: Letrozole Tablets IP 2.5mg
International Trade Name: Femara®

LETZORA is a high-quality Letrozole 2.5mg Tablet, a bioequivalent formulation of the internationally recognized aromatase inhibitor marketed under the brand name Femara®. Manufactured in WHO-GMP certified facilities, LETZORA Tablets are supplied by trusted pharmaceutical exporters from India to support global oncology and hormone therapy treatment programs, particularly in hormone receptor–positive breast cancer.

Letrozole works by inhibiting the aromatase enzyme, thereby significantly reducing estrogen production in postmenopausal women and slowing the growth of hormone-dependent breast cancer cells. LETZORA 2.5mg Tablet is primarily indicated for the treatment of estrogen receptor–positive early and advanced breast cancer, including adjuvant therapy, extended adjuvant treatment, and therapy following progression on anti-estrogen treatments such as tamoxifen.

Letrozole 2.5mg tablet, LETZORA tablet, Femara generic, aromatase inhibitor price, hormone-positive breast cancer treatment, oral endocrine therapy, anticancer tablets exporter India, and oncology pharmaceutical manufacturer India.

LETZORA Letrozole Tablet is manufactured under stringent GMP and pharmaceutical quality standards, ensuring consistent efficacy, safety, and long-term stability. The tablets are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology clinics, hospitals, government cancer programs, and international pharmaceutical distributors.

Fulvekast 250mg Injection is an anti-cancer medication used in the treatment of hormone receptor-positive breast cancer in postmenopausal women. It contains Fulvestrant, an estrogen receptor antagonist that works by blocking the effects of estrogen, thereby slowing down or stopping the growth of cancer cells.

This injection is administered intramuscularly under the supervision of a qualified healthcare professional. It is commonly prescribed in cases where breast cancer is hormone-dependent and helps improve treatment outcomes by controlling tumor progression.

Key Features:

• Contains Fulvestrant 250mg
• Effective anti-estrogen therapy for breast cancer
• Helps slow down cancer cell growth
• Long-acting intramuscular injection

Indications:

• Hormone receptor-positive breast cancer (postmenopausal women)

Common Side Effects:

• Nausea and vomiting
• Injection site pain
• Fatigue
• Back pain
• Hot flashes
• Headache
• Loss of appetite

Storage:
Store in a refrigerator (2°C – 8°C). Do not freeze.

Usage Instructions:
To be administered by a healthcare professional only. Do not self-administer.

Note:
Use strictly under medical prescription.

ASTRAZYRA Tablet
Composition: Anastrozole Tablets 1mg
International Trade Name: Arimidex®

ASTRAZYRA is a high-quality Anastrozole 1mg Tablet, a bioequivalent formulation of the internationally recognized aromatase inhibitor marketed under the brand name Arimidex®. Manufactured in WHO-GMP certified facilities, ASTRAZYRA Tablets are supplied by trusted pharmaceutical exporters from India to support global oncology and hormone therapy treatment programs, particularly in hormone receptor–positive breast cancer.

Anastrozole works by inhibiting the aromatase enzyme, thereby reducing estrogen production in postmenopausal women, which helps slow or stop the growth of hormone-dependent breast cancer cells. ASTRAZYRA 1mg Tablet is primarily indicated for the treatment of estrogen receptor–positive early and advanced breast cancer in postmenopausal women, including adjuvant therapy and treatment following progression on tamoxifen.

Anastrozole 1mg tablet, ASTRAZYRA tablet, Arimidex generic, aromatase inhibitor price, hormone-positive breast cancer treatment, oral endocrine therapy, anticancer tablets exporter India, and oncology pharmaceutical manufacturer India.

ASTRAZYRA Anastrozole Tablet is manufactured under stringent GMP and pharmaceutical quality standards, ensuring consistent efficacy, safety, and long-term stability. The tablets are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology clinics, hospitals, government cancer programs, and international pharmaceutical distributors.

NOVO Meropenem Injection
Composition: Meropenem for Injection 1000mg
International Trade Name: Merrem®

NOVO Meropenem 1000 is a high-quality Meropenem 1000mg Injection, a bioequivalent formulation of the internationally recognized broad-spectrum carbapenem antibiotic marketed under the brand name Merrem®. Manufactured in WHO-GMP certified facilities, NOVO Meropenem Injection is supplied by trusted pharmaceutical exporters from India, backed by a legacy of pharmaceutical excellence since 1946, to support global hospital and critical care treatment programs.

Meropenem is a potent beta-lactam antibiotic belonging to the carbapenem class, with broad activity against gram-positive, gram-negative, and anaerobic bacteria, including many multi-drug-resistant organisms. NOVO Meropenem 1000mg Injection is primarily indicated for the treatment of severe bacterial infections such as pneumonia, intra-abdominal infections, meningitis, septicemia, skin and soft tissue infections, and complicated urinary tract infections, especially in hospitalized and critically ill patients.

Meropenem 1g injection, NOVO Meropenem injection, Merrem generic, carbapenem antibiotic price, severe bacterial infection treatment, ICU antibiotic injection, hospital injectables exporter India, and sterile injectable manufacturer India.

NOVO Meropenem 1000 Injection is manufactured under stringent GMP and sterile injectable quality standards, ensuring consistent potency, safety, and stability. The injection is supplied in secure, sterile, export-grade packaging with complete regulatory documentation, making it suitable for hospitals, intensive care units, emergency departments, government health programs, and international pharmaceutical distributors.

PALBOCIB 125 MG TAB

Composition: PALBOCICLIB 125 mg 

International Trade Name: Ibrance®

Palbocib 125 mg (Palbociclib Capsules) is a targeted oral anti-cancer medication used in the treatment of hormone receptor-positive (HR+), HER2-negative advanced or metastatic breast cancer. It contains Palbociclib 125 mg, a cyclin-dependent kinase (CDK 4/6) inhibitor that works by blocking proteins responsible for cancer cell division, thereby slowing tumor growth and progression.

Palbociclib is globally recognized under the well-known international brand name Ibrance® (by Pfizer) and is widely prescribed across the USA, Europe, and other international markets. Palbocib 125 mg is a high-quality generic alternative that provides the same therapeutic effectiveness at a more affordable price.

This medication is commonly used in combination with hormonal therapies such as letrozole or fulvestrant to enhance treatment outcomes. It helps delay disease progression, improve survival rates, and maintain better quality of life in patients with advanced breast cancer.

Key Benefits:

• Inhibits cancer cell division (CDK 4/6 inhibition)

• Effective in HR+ / HER2- breast cancer

• Helps slow tumor growth and spread

• Improves progression-free survival

Usage Instructions:
Take Palbocib 125 mg exactly as prescribed by your healthcare provider, usually once daily for 21 days followed by 7 days off (28-day cycle). It should be taken with food.

Safety Information:
Use under strict medical supervision. Regular monitoring of blood counts is essential, as this medicine may lower white blood cell levels and increase infection risk.

International Brand Names of Palbociclib:
Ibrance®, Palbociclib Teva, Palbonix, and other branded generics available worldwide.

Halkeran 5mg Tablet
Composition: Chlorambucil Tablets 5mg
International Trade Name: Leukeran®

Halkeran 5 is a high-quality Chlorambucil 5mg Tablet, a bioequivalent formulation of the internationally recognized alkylating anticancer agent marketed under the brand name Leukeran®. Manufactured in WHO-GMP certified facilities, Halkeran Tablets are supplied by trusted pharmaceutical exporters from India to support global hematology and oncology treatment programs, particularly in lymphoproliferative disorders.

Chlorambucil is a nitrogen mustard alkylating agent that interferes with DNA replication and transcription, leading to inhibition of rapidly dividing malignant cells. Halkeran 5mg Tablet is primarily indicated for the treatment of chronic lymphocytic leukemia (CLL), Hodgkin’s and non-Hodgkin’s lymphomas, and certain other lymphoid malignancies, either as monotherapy or as part of combination chemotherapy regimens.

Halkeran 5mg Tablet is manufactured under stringent GMP and pharmaceutical quality standards to ensure consistent efficacy, safety, and batch-to-batch reliability. The product is supplied in secure, export-grade packaging with complete regulatory documentation, making it suitable for oncology hospitals, hematology clinics, specialty pharmacies, government cancer programs, and international pharmaceutical distributors.

Regonat Tablet
Composition: Regorafenib Tablets 40mg
International Trade Names: Stivarga®, Regonix®

Regonat is a high-quality Regorafenib 40mg Tablet, a bioequivalent formulation of the internationally recognized multi-kinase inhibitor marketed under the brand names Stivarga® and Regonix®. Manufactured in WHO-GMP certified facilities, Regonat Tablets are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs.

Regorafenib is an oral multi-targeted tyrosine kinase inhibitor that blocks multiple protein kinases involved in tumor angiogenesis, oncogenesis, and the tumor microenvironment. Regonat 40mg Tablet is primarily indicated for the treatment of metastatic colorectal cancer, gastrointestinal stromal tumors (GIST), and hepatocellular carcinoma (HCC) in patients who have previously received standard therapies.

Regorafenib 40mg tablet, Regonat tablet, Stivarga generic, Regonix equivalent, multi-kinase inhibitor price, colorectal cancer treatment tablets, GIST therapy, liver cancer targeted therapy, oncology medicines exporter India, and anticancer tablet manufacturer India.

Regonat Regorafenib Tablet is manufactured under stringent GMP and pharmaceutical quality standards, ensuring consistent efficacy, safety, and long-term stability. The tablets are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology clinics, tertiary care hospitals, cancer institutes, government cancer programs, and international pharmaceutical distributors.

Tacrograf 0.1 Capsule
Composition: Tacrolimus Capsules 0.1mg
International Trade Name: Prograf®

Tacrograf 0.1 is a high-quality Tacrolimus 0.1mg Capsule, a bioequivalent formulation of the internationally recognized calcineurin inhibitor marketed under the brand name Prograf®. Manufactured in WHO-GMP certified facilities, Tacrograf Capsules are supplied by trusted pharmaceutical exporters from India to support global transplant and immunosuppressive therapy programs.

Tacrolimus is a potent immunosuppressant that inhibits T-lymphocyte activation by blocking calcineurin-dependent cytokine transcription. Tacrograf 0.1mg Capsule is primarily indicated for the prevention of organ rejection in patients undergoing kidney, liver, or heart transplantation, and is also used in selected autoimmune and inflammatory conditions under specialist supervision, particularly where low-dose tacrolimus is clinically required.

Tacrolimus 0.1mg capsule, Tacrograf 0.1 capsule, Prograf generic, low-dose immunosuppressant price, transplant rejection prevention therapy, calcineurin inhibitor capsule, transplant medicines exporter India, and immunosuppressive drug manufacturer India.

Tacrograf 0.1 Tacrolimus Capsule is manufactured under stringent GMP and pharmaceutical quality standards, ensuring consistent potency, safety, and long-term stability. The capsules are supplied in secure, moisture-protected, export-grade packaging with complete regulatory documentation, making them suitable for transplant centers, tertiary care hospitals, pediatric transplant units, specialty clinics, government health programs, and international pharmaceutical distributors.

• PALBOMYRA 125 Capsule
  Composition: Palbociclib Capsules 125mg
  International Trade Name: Ibrance®

  PALBOMYRA 125 is a high-quality Palbociclib 125mg Capsule, a bioequivalent formulation of the internationally recognized CDK4/6 inhibitor marketed under the brand name Ibrance®. Manufactured in WHO-GMP certified facilities, PALBOMYRA Capsules are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in hormone receptor–positive breast cancer.

  Palbociclib is a selective cyclin-dependent kinase (CDK) 4 and 6 inhibitor that works by blocking cell-cycle progression, thereby inhibiting the proliferation of cancer cells. PALBOMYRA 125mg Capsule is primarily indicated for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer, especially in combination with endocrine therapies such as aromatase inhibitors or fulvestrant, in patients previously treated with hormonal therapy.

  Palbociclib 125mg capsule, PALBOMYRA 125 capsule, Ibrance biosimilar, CDK4/6 inhibitor price, HR-positive HER2-negative breast cancer treatment, targeted oral oncology therapy, anticancer capsule exporter India, and oncology pharmaceutical manufacturer India.

  PALBOMYRA 125 Palbociclib Capsule is manufactured under stringent GMP and oncology quality standards, ensuring consistent efficacy, safety, and long-term stability. The capsules are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology clinics, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Tacrograf 0.5 Capsule
Composition: Tacrolimus Capsules 0.5mg
International Trade Name: Prograf®

Tacrograf 0.5 is a high-quality Tacrolimus 0.5mg Capsule, a bioequivalent formulation of the internationally recognized calcineurin inhibitor marketed under the brand name Prograf®. Manufactured in WHO-GMP certified facilities, Tacrograf Capsules are supplied by trusted pharmaceutical exporters from India to support global transplant and immunosuppressive therapy programs.

Tacrolimus is a potent immunosuppressant that inhibits T-lymphocyte activation by blocking calcineurin-dependent cytokine transcription. Tacrograf 0.5mg Capsule is primarily indicated for the prevention of organ rejection in patients undergoing kidney, liver, or heart transplantation, and is also used in selected autoimmune and inflammatory conditions under specialist supervision.

Tacrolimus 0.5mg capsule, Tacrograf 0.5 capsule, Prograf generic, immunosuppressant capsule price, organ transplant rejection prevention, calcineurin inhibitor therapy, transplant medicines exporter India, and immunosuppressive drug manufacturer India.

Tacrograf 0.5 Tacrolimus Capsule is manufactured under stringent GMP and pharmaceutical quality standards, ensuring consistent potency, safety, and long-term stability. The capsules are supplied in secure, moisture-protected, export-grade packaging with complete regulatory documentation, making them suitable for transplant centers, tertiary care hospitals, specialty clinics, government health programs, and international pharmaceutical distributors.

• Piclib Capsule
  Composition: Palbociclib Capsules 125mg
  International Trade Name: Ibrance®

  Piclib 125 is a high-quality Palbociclib 125mg Capsule, a bioequivalent formulation of the internationally recognized CDK4/6 inhibitor marketed under the brand name Ibrance®. Manufactured in WHO-GMP certified facilities, Piclib Capsules are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in hormone receptor–positive breast cancer.

  Palbociclib is a selective cyclin-dependent kinase (CDK) 4 and 6 inhibitor that works by blocking cell-cycle progression, thereby inhibiting the proliferation of cancer cells. Piclib 125 Capsule is primarily indicated for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer, especially in combination with endocrine therapies such as aromatase inhibitors or fulvestrant, in patients previously treated with hormonal therapy.

  Palbociclib 125mg capsule, Piclib capsule, Ibrance biosimilar, CDK4/6 inhibitor price, HR-positive HER2-negative breast cancer treatment, targeted oral oncology therapy, anticancer capsule exporter India, and oncology pharmaceutical manufacturer India.

  Piclib Palbociclib Capsule is manufactured under stringent GMP and oncology quality standards, ensuring consistent efficacy, safety, and long-term stability. The capsules are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology clinics, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

PALBOMYRA 75 Capsule
Composition: Palbociclib Capsules 75mg
International Trade Name: Ibrance®

PALBOMYRA 75 is a high-quality Palbociclib 75mg Capsule, a bioequivalent formulation of the internationally recognized CDK4/6 inhibitor marketed under the brand name Ibrance®. Manufactured in WHO-GMP certified facilities, PALBOMYRA Capsules are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in hormone receptor–positive breast cancer.

Palbociclib is a selective cyclin-dependent kinase (CDK) 4 and 6 inhibitor that works by blocking cell-cycle progression, thereby inhibiting the proliferation of cancer cells. PALBOMYRA 75mg Capsule is primarily indicated for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer, especially in combination with endocrine therapies such as aromatase inhibitors or fulvestrant, in patients previously treated with hormonal therapy.

Palbociclib 75mg capsule, PALBOMYRA 75 capsule, Ibrance biosimilar, CDK4/6 inhibitor price, HR-positive HER2-negative breast cancer treatment, targeted oral oncology therapy, anticancer capsule exporter India, and oncology pharmaceutical manufacturer India.

PALBOMYRA 75 Palbociclib Capsule is manufactured under stringent GMP and oncology quality standards, ensuring consistent efficacy, safety, and long-term stability. The capsules are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology clinics, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Geffy 250 Tablet
Composition: Gefitinib Tablets 250mg
International Trade Name: Iressa®

Geffy 250 is a high-quality Gefitinib 250mg Tablet, a bioequivalent formulation of the internationally recognized epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor marketed under the brand name Iressa®. Manufactured in WHO-GMP certified facilities, Geffy Tablets are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs.

Gefitinib is a targeted anticancer agent that selectively inhibits EGFR tyrosine kinase activity, thereby blocking downstream signaling pathways responsible for tumor cell proliferation and survival. Geffy 250mg Tablet is primarily indicated for the treatment of non-small cell lung cancer (NSCLC) with activating EGFR mutations, particularly in patients who have progressed on or are intolerant to prior chemotherapy.

Gefitinib 250mg tablet, Geffy 250 tablet, Iressa generic, EGFR inhibitor price, NSCLC targeted therapy, lung cancer treatment tablets, oncology medicine exporter India, and anticancer tablet manufacturer India.

Geffy 250 Gefitinib Tablet is manufactured under stringent GMP and pharmaceutical quality standards, ensuring consistent efficacy, safety, and long-term stability. The tablets are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology clinics, hospitals, cancer treatment centers, government cancer programs, and international pharmaceutical distributors.

Geffy 250 Tablet
Composition: Gefitinib Tablets 250mg
International Trade Name: Iressa®

Geffy 250 is a high-quality Gefitinib 250mg Tablet, a bioequivalent formulation of the internationally recognized epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor marketed under the brand name Iressa®. Manufactured in WHO-GMP certified facilities, Geffy Tablets are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs.

Gefitinib is a targeted anticancer agent that selectively inhibits EGFR tyrosine kinase activity, thereby blocking downstream signaling pathways responsible for tumor cell proliferation and survival. Geffy 250mg Tablet is primarily indicated for the treatment of non-small cell lung cancer (NSCLC) with activating EGFR mutations, particularly in patients who have progressed on or are intolerant to prior chemotherapy.

Gefitinib 250mg tablet, Geffy 250 tablet, Iressa generic, EGFR inhibitor price, NSCLC targeted therapy, lung cancer treatment tablets, oncology medicine exporter India, and anticancer tablet manufacturer India.

Geffy 250 Gefitinib Tablet is manufactured under stringent GMP and pharmaceutical quality standards, ensuring consistent efficacy, safety, and long-term stability. The tablets are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology clinics, hospitals, cancer treatment centers, government cancer programs, and international pharmaceutical distributors.

Tamoxol 10mg Tablet
Composition: Tamoxifen Tablets 10mg
International Trade Name: Nolvadex®

Tamoxol 10 is a high-quality Tamoxifen 10mg Tablet, a bioequivalent formulation of the internationally recognized selective estrogen receptor modulator (SERM) marketed under the brand name Nolvadex®. Manufactured in WHO-GMP certified facilities, Tamoxol Tablets are supplied by trusted pharmaceutical exporters from India to support global oncology and hormone-therapy treatment programs, particularly in estrogen receptor (ER)–positive breast cancer.

Tamoxifen works by competitively binding to estrogen receptors in breast tissue, thereby inhibiting estrogen-stimulated tumor growth. Tamoxol 10mg Tablet is primarily indicated for the treatment and prevention of ER-positive breast cancer in both premenopausal and postmenopausal women, and is also used in male breast cancer and other hormone-responsive conditions as directed by oncologists.

Tamoxol 10mg Tablet is manufactured under stringent GMP and pharmaceutical quality standards to ensure consistent potency, safety, and therapeutic reliability. The product is supplied in secure, export-grade packaging with complete regulatory documentation, making it suitable for oncology hospitals, breast cancer clinics, specialty pharmacies, government cancer programs, and international pharmaceutical distributors.

Pomalid 1mg Capsule
Composition: Pomalidomide Capsules 1mg
International Trade Name: Pomalyst® / Imnovid®

Pomalid 1 is a high-quality Pomalidomide 1mg Capsule, a bioequivalent formulation of the internationally recognized immunomodulatory anticancer drug marketed under the brand names Pomalyst® and Imnovid®. Manufactured in WHO-GMP certified facilities, Pomalid Capsules are supplied by trusted pharmaceutical exporters from India to support advanced global hematology and oncology treatment programs, particularly in multiple myeloma.

Pomalidomide is a third-generation immunomodulatory agent (IMiD) that exerts anti-myeloma activity by enhancing immune-mediated tumor cell destruction, inhibiting angiogenesis, and inducing apoptosis in malignant plasma cells. Pomalid 1mg Capsule is primarily indicated for the treatment of relapsed or refractory multiple myeloma (RRMM) in patients who have received prior therapies, including lenalidomide and proteasome inhibitors, commonly used in combination with dexamethasone.

Pomalid 1mg Capsule is manufactured under stringent GMP and pharmaceutical quality standards to ensure consistent potency, safety, and therapeutic reliability. The product is supplied in secure, export-grade packaging with complete regulatory documentation, making it suitable for oncology hospitals, hematology clinics, specialty pharmacies, government cancer programs, and international pharmaceutical distributors.

• Ciclib Capsule
  Composition: Palbociclib Capsules 125mg
  International Trade Name: Ibrance®

  Ciclib 125 is a high-quality Palbociclib 125mg Capsule, a bioequivalent formulation of the internationally recognized CDK4/6 inhibitor marketed under the brand name Ibrance®. Manufactured in WHO-GMP certified facilities, Ciclib Capsules are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in hormone receptor–positive breast cancer.

  Palbociclib is a selective cyclin-dependent kinase (CDK) 4 and 6 inhibitor that works by blocking cell-cycle progression, thereby inhibiting the proliferation of cancer cells. Ciclib 125 Capsule is primarily indicated for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer, especially in combination with endocrine therapies such as aromatase inhibitors or fulvestrant, in patients previously treated with hormonal therapy.

  Palbociclib 125mg capsule, Ciclib capsule, Ibrance biosimilar, CDK4/6 inhibitor price, HR-positive HER2-negative breast cancer treatment, targeted oral oncology therapy, anticancer capsule exporter India, and oncology pharmaceutical manufacturer India.

  Ciclib Palbociclib Capsule is manufactured under stringent GMP and oncology quality standards, ensuring consistent efficacy, safety, and long-term stability. The capsules are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology clinics, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Priunta Injection
Composition: Trastuzumab for Injection 440mg
International Trade Name: Herceptin®

Priunta 440 is a high-quality Trastuzumab 440mg Injection, a biosimilar formulation of the internationally recognized HER2-targeted monoclonal antibody marketed under the brand name Herceptin®. Manufactured in WHO-GMP certified facilities, Priunta Injection is supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in HER2-positive breast cancer.

Trastuzumab is a humanized monoclonal antibody that binds to the HER2 receptor on cancer cells, inhibiting proliferation and tumor growth. Priunta 440mg Injection is primarily indicated for the treatment of HER2-positive early and metastatic breast cancer, as well as HER2-positive gastric cancer, either as monotherapy or in combination with chemotherapy, particularly in patients previously treated with taxane or trastuzumab therapy.

Trastuzumab 440mg injection, Priunta injection, Herceptin biosimilar, HER2-positive breast cancer therapy, monoclonal antibody oncology injection, biologics exporter India, and anticancer injectable manufacturer India.

Priunta Trastuzumab Injection is manufactured under stringent GMP and biologics quality standards, ensuring consistent efficacy, safety, and long-term stability. The injection is supplied in secure, cold-chain compliant, export-grade packaging with complete regulatory documentation, making it suitable for oncology infusion centers, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Palbojas Capsule
Composition: Palbociclib Capsules 125mg
International Trade Name: Ibrance®

Palbojas 125 is a high-quality Palbociclib 125mg Capsule, a bioequivalent formulation of the internationally recognized CDK4/6 inhibitor marketed under the brand name Ibrance®. Manufactured in WHO-GMP certified facilities, Palbojas Capsules are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in hormone receptor–positive breast cancer.

Palbociclib is a selective cyclin-dependent kinase (CDK) 4 and 6 inhibitor that works by blocking cell-cycle progression, thereby inhibiting the proliferation of cancer cells. Palbojas 125 Capsule is primarily indicated for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer, especially in combination with endocrine therapies such as aromatase inhibitors or fulvestrant, in patients previously treated with hormonal therapy.

Palbociclib 125mg capsule, Palbojas capsule, Ibrance biosimilar, CDK4/6 inhibitor price, HR-positive HER2-negative breast cancer treatment, targeted oral oncology therapy, anticancer capsule exporter India, and oncology pharmaceutical manufacturer India.

Palbojas Palbociclib Capsule is manufactured under stringent GMP and oncology quality standards, ensuring consistent efficacy, safety, and long-term stability. The capsules are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology clinics, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

CAPSY 500 Tablet
Composition: Capecitabine Tablets IP 500mg
International Trade Name: Xeloda®

CAPSY 500 is a high-quality Capecitabine 500mg Tablet, a bioequivalent formulation of the internationally recognized oral fluoropyrimidine anticancer agent marketed under the brand name Xeloda®. Manufactured in WHO-GMP certified facilities, CAPSY Tablets are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs.

Capecitabine is a prodrug that is enzymatically converted into 5-fluorouracil (5-FU) within tumor tissues, enabling targeted cytotoxic activity while minimizing systemic toxicity. CAPSY 500mg Tablet is primarily indicated for the treatment of breast cancer, colorectal cancer, and gastric cancer, either as monotherapy or in combination with other chemotherapeutic agents, in both adjuvant and metastatic settings.

Capecitabine 500mg tablet, CAPSY 500 tablet, Xeloda generic, oral chemotherapy tablet price, colorectal cancer treatment, breast cancer chemotherapy, oncology tablets exporter India, and anticancer pharmaceutical manufacturer India.

CAPSY Capecitabine Tablet is manufactured under stringent GMP and oncology quality standards, ensuring consistent efficacy, safety, and long-term stability. The tablets are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology clinics, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Femistra Tablet
Composition: Anastrozole Tablets IP 1mg
International Trade Name: Arimidex®

Femistra is a high-quality Anastrozole 1mg Tablet, a bioequivalent formulation of the internationally recognized aromatase inhibitor marketed under the brand name Arimidex®. Manufactured in WHO-GMP certified facilities, Femistra Tablets are supplied by trusted pharmaceutical exporters from India to support global oncology and hormone therapy treatment programs, particularly in hormone receptor–positive breast cancer.

Anastrozole works by inhibiting the aromatase enzyme, thereby reducing estrogen production in postmenopausal women, which helps slow or stop the growth of hormone-dependent breast cancer cells. Femistra 1mg Tablet is primarily indicated for the treatment of estrogen receptor–positive early and advanced breast cancer, including adjuvant therapy and therapy following progression on tamoxifen.

Anastrozole 1mg tablet, Femistra tablet, Arimidex generic, aromatase inhibitor price, hormone-positive breast cancer treatment, oral endocrine therapy, anticancer tablets exporter India, and oncology pharmaceutical manufacturer India.

Femistra Anastrozole Tablet is manufactured under stringent GMP and pharmaceutical quality standards, ensuring consistent efficacy, safety, and long-term stability. The tablets are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology clinics, hospitals, government cancer programs, and international pharmaceutical distributors.

Etibo 250 Tablet
Composition: Lapatinib Tablets 250mg
International Trade Name: Tykerb®

Etibo 250 is a high-quality Lapatinib 250mg Tablet, a bioequivalent formulation of the internationally recognized dual tyrosine kinase inhibitor marketed under the brand name Tykerb®. Manufactured in WHO-GMP certified facilities, Etibo Tablets are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in HER2-positive breast cancer.

Lapatinib is a selective dual inhibitor of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), helping to block tumor cell growth and proliferation. Etibo 250mg Tablet is primarily indicated for the treatment of HER2-positive advanced or metastatic breast cancer, especially in combination with capecitabine or letrozole, in patients who have progressed following prior anti-HER2 therapy.

Lapatinib 250mg tablet, Etibo 250 tablet, Tykerb generic, HER2-positive breast cancer treatment, dual tyrosine kinase inhibitor price, oral targeted oncology therapy, anticancer tablets exporter India, and oncology pharmaceutical manufacturer India.

Etibo 250 Lapatinib Tablet is manufactured under stringent GMP and oncology quality standards, ensuring consistent efficacy, safety, and long-term stability. The tablets are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology clinics, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Capiibine 500mg Tablet
Composition: Capecitabine Tablets 500mg
International Trade Name: Xeloda®

Capiibine 500 is a high-quality Capecitabine 500mg Tablet, a bioequivalent formulation of the internationally recognized oral fluoropyrimidine anticancer drug marketed under the brand name Xeloda®. Manufactured in WHO-GMP certified facilities, Capiibine Tablets are supplied by trusted pharmaceutical exporters from India to support global oncology treatment programs, particularly in colorectal, breast, and gastric cancers.

Capecitabine is a prodrug of 5-fluorouracil (5-FU) that undergoes enzymatic conversion in tumor tissues to active 5-FU, selectively inhibiting DNA synthesis and tumor cell proliferation. Capiibine 500mg Tablet is primarily indicated for the treatment of metastatic colorectal cancer, adjuvant treatment of colon cancer, metastatic breast cancer, and gastric cancer, either as monotherapy or in combination with other chemotherapeutic agents.

Capiibine 500mg Tablet is manufactured under stringent GMP and pharmaceutical quality standards to ensure consistent potency, safety, and therapeutic reliability. The product is supplied in secure, export-grade packaging with complete regulatory documentation, making it suitable for oncology hospitals, chemotherapy clinics, specialty pharmacies, government cancer programs, and international pharmaceutical distributors.

Capegard 500mg Tablet
Composition: Capecitabine Tablets 500mg
International Trade Name: Xeloda®

Capegard 500 is a high-quality Capecitabine 500mg Tablet, a bioequivalent formulation of the internationally recognized oral fluoropyrimidine anticancer drug marketed under the brand name Xeloda®. Manufactured in WHO-GMP certified facilities, Capegard Tablets are supplied by trusted pharmaceutical exporters from India to support global oncology treatment programs, particularly in colorectal, breast, and gastric cancers.

Capecitabine is a prodrug of 5-fluorouracil (5-FU) that is selectively converted into active 5-FU in tumor tissues, inhibiting DNA synthesis and tumor cell proliferation. Capegard 500mg Tablet is primarily indicated for the treatment of metastatic colorectal cancer, adjuvant therapy for colon cancer, metastatic breast cancer, and gastric cancer, either as monotherapy or in combination with other chemotherapeutic agents.

Capegard 500mg Tablet is manufactured under stringent GMP and pharmaceutical quality standards to ensure consistent potency, safety, and therapeutic reliability. The product is supplied in secure, export-grade packaging with complete regulatory documentation, making it suitable for oncology hospitals, chemotherapy clinics, specialty pharmacies, government cancer programs, and international pharmaceutical distributors.

Megasty 160 Tablet
Composition: Megestrol Acetate Tablets IP 160mg
International Trade Name: Megace®

Megasty 160 is a high-quality Megestrol Acetate 160mg Tablet, a bioequivalent formulation of the internationally recognized progestational agent marketed under the brand name Megace®. Manufactured in WHO-GMP certified facilities, Megasty Tablets are supplied by trusted pharmaceutical exporters from India to support global oncology and supportive care treatment programs.

Megestrol acetate is a synthetic progestin with appetite-stimulating and antineoplastic properties, widely used to manage cancer-related cachexia and hormone-sensitive malignancies. Megasty 160mg Tablet is primarily indicated for the treatment of advanced breast cancer and endometrial cancer, as well as for the management of anorexia, cachexia, or significant weight loss in patients with cancer or AIDS.

Megestrol acetate 160mg tablet, Megasty 160 tablet, Megace generic, appetite stimulant tablet price, cancer cachexia management, hormone therapy for breast cancer, supportive oncology care tablets exporter India, and pharmaceutical manufacturer India.

Megasty 160 Megestrol Acetate Tablet is manufactured under stringent GMP and pharmaceutical quality standards, ensuring consistent efficacy, safety, and long-term stability. The tablets are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology clinics, hospitals, palliative care centers, government health programs, and international pharmaceutical distributors.

Capelieva 500mg Tablet
Composition: Capecitabine Tablets 500mg
International Trade Name: Xeloda®

Capelieva 500 is a high-quality Capecitabine 500mg Tablet, a bioequivalent formulation of the internationally recognized oral fluoropyrimidine anticancer drug marketed under the brand name Xeloda®. Manufactured in WHO-GMP certified facilities, Capelieva Tablets are supplied by trusted pharmaceutical exporters from India to support global oncology treatment programs, particularly in colorectal, breast, and gastric cancers.

Capecitabine is a prodrug of 5-fluorouracil (5-FU) that is enzymatically converted into active 5-FU in tumor tissues, selectively inhibiting DNA synthesis and tumor cell proliferation. Capelieva 500mg Tablet is primarily indicated for the treatment of metastatic colorectal cancer, adjuvant therapy for colon cancer, metastatic breast cancer, and gastric cancer, either as monotherapy or in combination with other chemotherapeutic agents.

Capelieva 500mg Tablet is manufactured under stringent GMP and pharmaceutical quality standards to ensure consistent potency, safety, and therapeutic reliability. The product is supplied in secure, export-grade packaging with complete regulatory documentation, making it suitable for oncology hospitals, chemotherapy clinics, specialty pharmacies, government cancer programs, and international pharmaceutical distributors.

Strosun 1mg Tablet
Composition: Anastrozole Tablets 1mg
International Trade Name: Arimidex®

Strosun 1 is a high-quality Anastrozole 1mg Tablet, a bioequivalent formulation of the internationally recognized aromatase inhibitor marketed under the brand name Arimidex®. Manufactured in WHO-GMP certified facilities, Strosun Tablets are supplied by trusted pharmaceutical exporters from India to support global oncology and hormone-therapy treatment programs, particularly in hormone receptor–positive breast cancer.

Anastrozole works by inhibiting the aromatase enzyme, thereby significantly reducing estrogen production in postmenopausal women and limiting estrogen-driven tumor growth. Strosun 1mg Tablet is primarily indicated for the treatment of postmenopausal women with estrogen receptor (ER)–positive early or advanced breast cancer, including adjuvant therapy and treatment of metastatic disease.

Strosun 1mg Tablet is manufactured under stringent GMP and pharmaceutical quality standards to ensure consistent potency, safety, and therapeutic reliability. The product is supplied in secure, export-grade packaging with complete regulatory documentation, making it suitable for oncology hospitals, breast cancer clinics, specialty pharmacies, government cancer programs, and international pharmaceutical distributors.

• Palbolieva Capsule
  Composition: Palbociclib Capsules 125mg
  International Trade Name: Ibrance®

  Palbolieva 125 is a high-quality Palbociclib 125mg Capsule, a bioequivalent formulation of the internationally recognized CDK4/6 inhibitor marketed under the brand name Ibrance®. Manufactured in WHO-GMP certified facilities, Palbolieva Capsules are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in hormone receptor–positive breast cancer.

  Palbociclib is a selective cyclin-dependent kinase (CDK) 4 and 6 inhibitor that works by blocking cell-cycle progression, thereby inhibiting the proliferation of cancer cells. Palbolieva 125 Capsule is primarily indicated for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer, especially in combination with endocrine therapies such as aromatase inhibitors or fulvestrant, in patients previously treated with hormonal therapy.

  Palbociclib 125mg capsule, Palbolieva capsule, Ibrance biosimilar, CDK4/6 inhibitor price, HR-positive HER2-negative breast cancer treatment, targeted oral oncology therapy, anticancer capsule exporter India, and oncology pharmaceutical manufacturer India.

  Palbolieva Palbociclib Capsule is manufactured under stringent GMP and oncology quality standards, ensuring consistent efficacy, safety, and long-term stability. The capsules are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology clinics, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.